Prosecution Insights
Last updated: November 04, 2026
Application No. 17/746,610

COMPOSITIONS FOR THE TREATMENT OF NEUROPATHIC PAIN AND SENSITIZATION OF TUMORS TO CHEMOTHERAPIES

Final Rejection §101§102§103§112
Filed
May 17, 2022
Priority
Aug 16, 2016 — provisional 62/375,820 +2 more
Examiner
BERTOGLIO, VALARIE E
Art Unit
1632
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Henry Ford Health System
OA Round
4 (Final)
64%
Grant Probability
Moderate
5-6
OA Rounds
0m
Est. Remaining
94%
With Interview

Examiner Intelligence

Grants 64% of resolved cases
64%
Career Allowance Rate
559 granted / 873 resolved
+4.0% vs TC avg
Strong +30% interview lift
Without
With
+30.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
46 currently pending
Career history
908
Total Applications
across all art units

Statute-Specific Performance

§101
4.1%
-35.9% vs TC avg
§103
26.7%
-13.3% vs TC avg
§102
15.4%
-24.6% vs TC avg
§112
41.7%
+1.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 873 resolved cases

Office Action

§101 §102 §103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicant’s reply dated 09/28/2026 has been received. Election/Restrictions Applicant’s election without traverse of claims 38-50 in the reply filed on 11/19/24 is acknowledged. Claim Objections Claim 38 is objected to because of the following informalities: Claim 38 at line 4 should read, “chemotherapeutic agent, the amount being sufficient to treat cancer;”. Claim 38 at line 5 should read, “a therapeutically effective amount of exosomes isolated from endothelial cells, the amount”. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 38-44 and 48-50 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 38 is unclear as to whether it may be intended to be a product or a method. As set forth below, a “regimen” is interpreted to be a “plan” and is neither a product nor a method. The claims do not recite any active method steps. The specification states, “The present invention therefor enables the chemotherapeutic agent to be administered or used in a dosage regimen at a concentration that is lower than the standard therapeutic dosage for administering the chemotherapeutic agent to a similar subject having the same or similar cancer.” (para 134). This and other recitations of the term “regimen” in the Specification, fail to define the term “regimen” in a way that clearly indicates it is a product or method and not a “treatment plan”. Claims 39-44 and 48-50 are unclear based upon their dependency from claim 38. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. The rejection of claims 38-44, 46-50 and 59-63 under 35 U.S.C. 101 because the claimed invention is directed to a natural phenomenon without significantly more is withdrawn. Claims 38-44, and 48-50 are newly rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. Based upon consideration of all of the relevant factors with respect to the claims as a whole, claims 38-44 and 48-50 are held to claim an abstract idea, and is therefore rejected as ineligible subject matter under 35 U.S.C. § 101. The rationale for this finding is explained below: The claims are drawn to “a dosage regimen” which is neither a product nor a process. A “regimen” is a “plan” which amounts to a mental activity which is not eligible subject matter under 35 USC 101. See Bilski v. Kappos, No. 08–964 (June 28, 2010). Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. The rejection of claim(s) 38-39, 41-44, 46-48, 50, 59, and 60-63 under 35 U.S.C. 102(a)(1) as being anticipated by Haqqani (Fluids and Barriers of the CNS 2013, 10:4, of record) as evidenced by Simpson et al (Proteomics, 8, 2008, pages 4083-4099, of record) and Burtenshaw (2022, Frontiers in Cell and Developmental Biology, 10:853451, 22 pages, newly cited) is withdrawn as Haqqani did not teach a dosage regime comprising a platinum based chemotherapeutic. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The rejection of claim(s) 38, 40 and 49 under 35 U.S.C. 103 as being unpatentable over Haqqani as evidenced by Simpson and Burtenshaw in view of Zhuang et al (Molecular Therapy, October 2011, Vol 19, No 10, pages 1769-1779) is withdrawn as none of the reference teache the now-claimed dosage regimen comprising a platinum-based chemotherapeutic. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to VALARIE BERTOGLIO whose telephone number is (571)272-0725. The examiner can normally be reached M-F 6AM-2:30PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Peter Paras can be reached at 571-272-4517. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. VALARIE E. BERTOGLIO, Ph.D. Examiner Art Unit 1632 /VALARIE E BERTOGLIO/Primary Examiner, Art Unit 1632
Read full office action

Prosecution Timeline

Show 3 earlier events
Sep 29, 2025
Non-Final Rejection mailed — §101, §102, §103
Mar 20, 2026
Response Filed
Jun 26, 2026
Non-Final Rejection mailed — §101, §102, §103
Aug 24, 2026
Interview Requested
Sep 16, 2026
Applicant Interview (Telephonic)
Sep 16, 2026
Examiner Interview Summary
Sep 28, 2026
Response Filed
Oct 27, 2026
Final Rejection mailed — §101, §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778983
METHODS OF PRODUCING HUMAN RPE CELLS AND PHARMACEUTICAL PREPARATIONS OF HUMAN RPE CELLS
2y 12m to grant Granted Nov 03, 2026
Patent 12766199
GENE THERAPY VECTORS FOR TREATING HEART DISEASE
3y 2m to grant Granted Oct 20, 2026
Patent 12767930
Method For Promoting Differentiation Of Pluripotent Stem Cells By Reducing Undifferentiated State Thereof
2y 2m to grant Granted Oct 20, 2026
Patent 12760271
MIDBRAIN DOPAMINE (DA) NEURONS FOR ENGRAFTMENT
2y 7m to grant Granted Oct 13, 2026
Patent 12747278
CHIMERIC ANTIGEN RECEPTOR FOR TREATMENT OF CANCER
3y 10m to grant Granted Sep 29, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
64%
Grant Probability
94%
With Interview (+30.1%)
3y 3m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 873 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month